Aloma Alcober
Psychiatry · Kissimmee, FLNPI 1558314153
Payments from drug & device makers
Across 801 payments — averaging $27.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Alkermes, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Axsome Therapeutics, Inc.$1K
- plus $6K from 23 others
What the payments were for
- Speaking & faculty fees$3,90018%
- Food & beverage$17,69681%
- Education$1791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 132 | $6,138 |
| Alkermes, Inc. | 76 | $2,651 |
| Otsuka America Pharmaceutical, Inc. | 97 | $2,035 |
| Neurocrine Biosciences, Inc. | 72 | $1,694 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,552 |
| Axsome Therapeutics, Inc. | 40 | $1,409 |
| Teva Pharmaceuticals USA, Inc. | 48 | $1,078 |
| Johnson & Johnson | 44 | $895 |
| Vanda Pharmaceuticals Inc. | 34 | $866 |
| Almatica Pharma LLC | 29 | $563 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $521 |
| Lundbeck LLC | 40 | $492 |
| Tris Pharma Inc | 24 | $490 |
| Sunovion Pharmaceuticals Inc. | 28 | $423 |
| E.r. Squibb & Sons, L.L.C. | 9 | $213 |
| Bausch Health US, LLC | 8 | $148 |
| Indivior Inc. | 7 | $121 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $72 |
| Ironshore Pharmaceuticals Inc. | 3 | $63 |
| Merck | 4 | $54 |
| Corium, LLC | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Lilly USA, LLC | 2 | $49 |
| Acadia Pharmaceuticals Inc | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Brainsway USA Inc | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $23 |
| Neuronetics, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$4,169
- ARISTADA$2,465
- LYBALVI$1,288
- Auvelity$719
- ARISTADA INITIO$616
- CAPLYTA$612
- REXULTI$331
- ABILIFY MAINTENA$237
- SPRAVATO$135
- AUSTEDO$125
- ABILIFY ASIMTUFII$125
- Fanapt$125
- INGREZZA$123
- Austedo XR$111
How this compares
$21,775 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 13 | $191,318 |
| IngrezzaValbenazine Tosylate | 16 | $128,123 |
| CaplytaLumateperone Tosylate | 19 | $29,178 |
| VraylarCariprazine Hcl | 14 | $19,371 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $10,232 |
| Vilazodone Hcl | 24 | $3,183 |
| Mirtazapine | 44 | $1,255 |
| Quetiapine Fumarate | 31 | $1,065 |
| Ziprasidone Hcl | 12 | $846 |
| Aripiprazole | 26 | $712 |
| Atomoxetine Hcl | 13 | $702 |
| Lamotrigine | 38 | $486 |
| Alprazolam | 55 | $427 |
| Bupropion XlBupropion Hcl | 18 | $405 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 27 | $378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,078 | $191,31813 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,694 | $128,12316 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,552 | $29,17819 claims |
| AbbVieVraylar | $6,138 | $19,37114 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,409 | $10,23212 claims |
| Almatica Pharma LLCSertraline Hcl | $563 | $8115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Kissimmee
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.